Previous 10 | Next 10 |
2023-03-22 14:09:27 ET Incyte ( NASDAQ: INCY ) announced Wednesday that the FDA cleared its intravenous PD-1 inhibitor Zynyz under the agency’s accelerated approval program for patients with Merkel cell carcinoma (MCC), a rare form of skin cancer. The agency has use...
— First regulatory approval for Incyte PD-1 inhibitor based on the results of the POD1UM-201 trial — Zynyz is also being studied in additional tumor types and in combination with other Incyte pipeline compounds Incyte (Nasdaq:INCY) today announced that the U.S. F...
2023-03-20 08:07:19 ET Incyte ( NASDAQ: INCY ) shares traded ~5% higher on Monday after announcing that its oral JAK1 inhibitor povorcitinib met the primary endpoint in a Phase 2b clinical trial for adults with vitiligo, a chronic autoimmune disease characterized by skin dep...
- Patients treated with povorcitinib experienced improvements in total body and facial repigmentation; investigational therapy was well tolerated - Results were featured as an oral presentation in a late-breaking abstract session at the 2023 American Academy of Dermatology (AAD) Annual ...
- Patients achieving a high level of facial repigmentation (≥F-VASI90) at Week 52 maintained durable response one year following withdrawal of treatment - Continued treatment with Opzelura for up to two years resulted in sustained facial repigmentation and further improvements in...
2023-03-17 15:00:22 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...
2023-03-16 06:31:14 ET Summary The pharma/biotech subsector is undervalued by 16% relative to 11-year averages. Healthcare equipment is the less attractive subsector regarding both valuation and quality. Fast facts on PBE, a biotechnology and genomics ETF. 10 stocks cheape...
2023-03-10 15:00:56 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...
2023-03-08 06:41:29 ET Fed Chairman Jerome Powell undercut pivot expectations and dented stocks and bonds in his recent Congressional testimony. The S&P 500 ( SP500 ) ( NYSEARCA: SPY ), Nasdaq ( COMP.IND ), Nasdaq 100 ( NDX ) ( QQQ ) and Dow ( DJI ...
2023-03-07 07:03:02 ET Caris Life Sciences (Caris) announces a strategic research partnership with Incyte ( NASDAQ: INCY ) to augment precision medicine approaches for Incyte's oncology pipeline. The partnership will apply Caris' data and analytics tools, comprehe...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...